Document is current

Article History

Received: 9 November 2022

Accepted: 4 January 2023

First Online: 2 February 2023

Declarations

:

: Hideaki Miyake received honoraria from Ono Pharmaceutical. Masayuki Takahashi received honoraria from Ono Pharmaceutical and Bristol-Myers Squibb. Mototsugu Oya received honoraria from Pfizer, Novartis, Bayer, MSD, Eisai, Ono Pharmaceutical, Bristol-Myers Squibb, Takeda Pharmaceutical and Merck Biopharma. Norihiko Tsuchiya received honoraria from Pfizer, Novartis, MSD, Eisai, Bristol-Myers Squibb, Takeda Pharmaceutical and Merck Biopharma, and support for attending meetings from Merck Biopharma. Naoya Masumori received honoraria from MSD, Bristol-Myers Squibb, Takeda Pharmaceutical and Ono Pharmaceutical. Hideyasu Matsuyama received grants from Janssen Pharma, Takeda Pharmaceutical, Baxter, KyowaKirin and Sanofi, and honoraria from Janssen Pharma, AstraZeneca, Merck Biopharma, Bayer, Astellas Pharma and Chugai. Wataru Obara received honoraria from Ono Pharmaceutical, Merck Biopharma, Takeda Pharmaceutical and Astellas Pharma. Nobuo Shinohara received grants from Ono Pharmaceutical, honoraria from Ono Pharmaceutical and Bristol-Myers Squibb, and support for attending meetings from Ono Pharmaceutical and Bristol-Myers Squibb. Masahiro Nozawa received honoraria from Takeda Pharmaceutical. Shusuke Akamatsu received grants from Astellas Pharma, AstraZeneca and Tosoh, and honoraria from Janssen Pharma, AstraZeneca, Bayer, Astellas Pharma, Sanofi and Takeda Pharmaceutical. Tomomi Kamba received honoraria from AstraZeneca and Merck Biopharma. Masatoshi Eto received from grants from Ono Pharmaceutical, and honoraria from Ono Pharmaceutical and Bristol-Myers Squibb. All other authors declare no conflicts of interests to the current manuscript.

: All participants provided written informed consent.

: The study protocol was approved by the institutional review board of each institute.